



UK Neuromuscular Translational Research Conference 2016

Medical Sciences Teaching Centre, Oxford, OX1 3PL

Tuesday 22 and Wednesday 23 March 2016

PROGRAMME

Day 1 – Tuesday 22nd March

08:45 – 09:15 Registration and Coffee

09:15 – 09:30 **Introduction**
Prof. Michael Hanna
UCL Institute of Neurology

09:30–11:00 Session 1: Genomic Therapies
Chairs: Prof. Francesco Muntoni and Prof. Dame Kay Davies

09:30 – 10:00 **Alternate translational initiation of dystrophin: clinical and therapeutic implications**
Prof. Kevin Flanigan, Nationwide Children’s Hospital, Ohio
(abstract S01)

10:00 – 10:30 **From pathogenesis to therapy in spinal muscular atrophy**
Prof. Francesco Muntoni, UCL Institute of Child Health
(abstract S02)

10:30 – 11:00 **Antisense targeting of 3’end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for Facioscapulohumeral Dystrophy: a new gene silencing approach**
Dr. Julie Dumonceaux, Institut de Myologie, Paris
(abstract S03)

11:00 – 11:30 **Coffee**

11:30 – 11:45 Platform presentation 1 (merged)
Results of North Star Ambulatory Assessments in the Phase 3 Ataluren Confirmatory Trial in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (ACT DMD)

Prof. Francesco Muntoni, UCL Institute of Child Health
ACT DMD: Effect of Ataluren on Timed Function Tests in Nonsense Mutation Duchenne Muscular Dystrophy
Prof. Nathalie Goemans, University Hospitals Leuven, Belgium
(abstract P03 and P04)

- 11:45 – 12:00 Platform presentation 2
Cell therapy for muscular dystrophy: lessons learned and a road to efficacy
Prof. Giulio Cossu, University of Manchester
(abstract P02)
- 12:00 – 12:15 Platform presentation 3
Charcot-Marie-Tooth and Centronuclear myopathy induced mechanistic impairment in endocytosis
Tayyibah Ali, Imperial College London
(abstract P01)
- 12:15 – 12:30 Platform presentation 4
Intestinal Pseudo-obstruction in Adult m.3243A>G-Related Mitochondrial Disease: An Under-Recognised and Poorly-Managed Clinical Entity
Yi Ng, Newcastle University
(abstract P47)
- 12:30 – 13:00 Lunch**
- 13:00 – 14:00 Poster guided tours session 1 of 3**
- 14:00 – 17:30 Session 2: Next generation biomarkers**
Chairs: Prof. Mary Reilly and Prof. Volker Straub
- 14:00 – 14:30 **Next generation in vivo imaging technologies in DMD - the BIOIMAGE-NMD programme**
Prof. Andy Blamire, Newcastle University
(abstract S04)
- 14:30 – 15:00 **MRI Biomarker Outcome Measures in Charcot-Marie-Tooth disease and Inclusion Body Myositis**
Dr. John Thornton, UCL Institute of Neurology
(abstract S05)
- 15:00 – 15:30 **Integration of pharmacodynamic biomarkers into a drug regulatory pipeline: Vamorolone/VBP15 in DMD**
Prof. Eric Hoffman, ReveraGen BioPharma, Children's National Medical Center, Washington
(abstract S06)

- 15:30 – 16:00** **Coffee**
- 16:00 – 17:00** **Poster guided tour session 2 of 3**
- 17:00 – 17:30 **Session2: next generation biomarkers (ctd...)**
Qualification of Novel Methodologies European regulatory perspective
 Dr. Maria Isaac, Senior Scientific Officer, EMA
 (abstract S07)
- 17:30 – 17:45 Platform presentation 5
Human, Fly and Cell models of Riboflavin Transporter Neuronopathy
 Andreea Manole, UCL Institute of Neurology
 (abstract P66)
- 17:45 – 18:00 Platform presentation 6
Impaired mitochondrial function in neuronal cells harbouring a dominant glycyl-tRNA synthetase mutation
 Veronica Boczonadi, Newcastle University
 (abstract P65)
- 18:00 – 18:15** **Robert Meadowcroft**
 CEO, MDUK
- 18:15 – 19:00 Drinks
- 19:30 **Gala Dinner**
 Keble College OX1 3PG (10 mins walk)
 (Dress code: smart / smart casual)

Day 2 – Wednesday 23rd March

- 08:30 – 09:30 **Poster guided tour session 3 of 3**
- 09:30 – 10:30 **Poster flash sessions** (see p.14 for list)
 Chaired by Prof. Michael Hanna, UCL Institute of Neurology
- 10:30 – 12:30** **Session 3: Big Data**
 Chairs: Prof. Hanns Lochmuller and Prof. Thomas Voit
- 10:30 – 11:00 **A Human Phenotype Ontology (HPO)-driven whole-genome analysis framework for effective identification of pathogenic regulatory variants in Mendelian disease**
 Prof. Peter Robinson, Charité Hospital Berlin
 (abstract S08)

- 11:00 – 11:30 **Big data, large sequencing challenges, and the technology behind it**
Dr. Ivo Gut, CNAG (National Centre for Genomic Analysis), Barcelona
(abstract S09)
- 11:30 – 12:00 **Coffee**
- 12:00 – 12:30 **Neurology and Neurodegeneration Genomics England Clinical Interpretation Partnership (Neuro-GeCIP)**
Prof. Henry Houlden, UCL Institute of Neurology
(abstract S10)
- 12:30 – 12:45 Platform presentation 7
Clinical and genetic analysis of CLCN1 mutations with dual inheritance pattern
Dr. Emma Matthews, UCL Institute of Neurology
(abstract P94)
- 12:45 – 13:00 Platform presentation 8
A GFPT1 deficient mouse model of Congenital Myasthenic Syndrome
Yasmin Issop, Newcastle University
(abstract P98)
- 13:00 – 14:00 **Lunch**
- 14:00 – 14:15 Platform presentation 9
Development of a cell-penetrating peptide for the delivery of antisense oligonucleotides to peripheral and CNS tissues of spinal muscular atrophy mice
Suzan M Hammond, University of Oxford
(abstract P84)
- 14:15 – 14:30 Platform presentation 10
Microvascular defect as potential peripheral target in spinal muscular atrophy
Haiyan Zhou, UCL Institute of Child Health
(abstract P85)
- 14:30 – 15:00 **MRC Strategic plan**
Kathryn Adcock
Head of Neurosciences and Mental Health
Medical Research Council
- 15:00 – 16:00 **John Newsom-Davis Lecture**
The congenital myasthenic syndromes: better treatments through an understanding of disease mechanisms

Prof. David Beeson, University of Oxford

16:00 – 16:30 Poster prizes and close

To Note: Those displaying posters. To allow for judging and poster sessions, posters should only be put up and taken down during these times.

Day 1 Tuesday 22 March

Posters up: 8.45 am to 9.15 am

Posters down: 18:15 – 18.45 pm

Day 2 Weds 23 March

Posters up: evening of 22nd 18.45 pm onwards OR by 8.15 am latest 23 March (first poster session of this day is at 8.30 am). Building access is from 8am.

Posters down: 16.30 onwards